CervoMed to present RewinD-LB Phase 2b data at ILBDC Jan 2025; topline due Dec 2024

CervoMed Inc.

Oral presentation of detailed safety/efficacy results from neflamapimod Phase 2b in DLB at ILBDC on Jan 31, 2025.
Topline results from RewinD-LB Phase 2b trial expected to be disclosed in December 2024.
CEO expresses confidence in trial design to detect statistically significant and clinically meaningful difference.
Baseline patient characteristics from RewinD-LB to be presented at CTAD conference.
No approved therapies for DLB; neflamapimod aims to address this unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.